Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Jan 06, 2022 7:53am
86 Views
Post# 34288269

RE:38 Likes on one page, a new record pump

RE:38 Likes on one page, a new record pump
Red~One wrote: Everytime we have another weak update telling us to expect more dilution and a new focus (new licence ), this BB get inundated with idiotic posts and pumps, insults and name calling. What a world we live in. But congratulations to those paid pumpers from the Insider sites, they singlehandedly manage to further alienate truth from lies, facts from fiction. Say anything bad or criticize the company and you are a shorter or a basher, scum. OMG. And the pumpers besides getting rewarded ALSO reward each other with, wait for it "LIKES" and lots of them 38 on this 1 page alone, they like each other. That's funny.



Please name a paid pumper. 

The weak update BTW was not intended for you but to provide a bacground for new investors when they are atracted to Clas as news comes out. 

Those loyal to long term investors who are opmistic on this stock do like each other, its call being supoortive. I am to take it you don't like the people who are positive on the the stock. And you shoud revisit the definition of a pumper is because you obviously don't know.

Will you change your tune when new financials are announced? Then Phase 1? and on we go.
<< Previous
Bullboard Posts
Next >>